US4626524A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiviral peptides
Assignee: General Hospital Corp
•
Filing: 1984-08-30
•
Granted: 1986-12-02
•
Expires: 2004-08-30
Abstract
Abstract The present invention provides peptides of a sequence which is similar or identical to the amino terminal sequence of the F1 chain of mumps virus. A variety of peptides are disclosed ranging from oligopeptides to dodecapeptides.
Inventors
- 👤 Alfred Server
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:12
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C07K5/00; C07K5/04; C07K5/10; C07K5/1002; C07K5/1016; A; A61; A61K; A61K38/00; C12; C12N; C12N2760/00; C12N2760/00011; C12N2760/18011; C12N2760/18711; C12N2760/18722
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
54 words
A peptide comprising the following sequence: X--NH--Ala--Gly--Y wherein X is D-- or ##STR3## where Z is hydrogen, C 1 -C 6 acyl, aroyl or an amino-protecting group; and Y is selected from the group consisting of Ile, Ile--Ala, Ile--Ala--Ile, Ile--Ala--Ile--Gly, Ile--Ala--Ile--Gly--Ile, Ile--Ala--Ile--Gly--Ile--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala--Glu, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala--Glu--Val, and Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala--Glu--Val--Thr.
Claim 2
Dependent Claim
54 words
A peptide comprising the following sequence: X--NH--Ala--Gly--Y wherein X is D-- or ##STR3## where Z is hydrogen, C 1 -C 6 acyl, aroyl or an amino-protecting group; and Y is selected from the group consisting of Ile, Ile--Ala, Ile--Ala--Ile, Ile--Ala--Ile--Gly, Ile--Ala--Ile--Gly--Ile, Ile--Ala--Ile--Gly--Ile--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala--Glu, Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala--Glu--Val, and Ile--Ala--Ile--Gly--Ile--Ala--Ala--Leu--Gly--Val--Ala--Thr--Ala--Ala--Glu--Val--Thr.
Claim 3
Dependent Claim
9 words
The peptide of claim 1 wherein X is ##STR4##
Claim 4
Dependent Claim
9 words
The peptide of claim 1 wherein X is ##STR5##
Claim 5
Dependent Claim
14 words
The peptide of any of claims 1, 2 or 3 wherein Y is Ile.
Claim 6
Dependent Claim
14 words
The peptide of any of claims 1, 2 or 3 wherein Y is Ile--Ala.
Claim 7
Dependent Claim
14 words
The peptide of any of claims 1, 2 or 3 wherein Y is Ile--Ala--Ile.
Claim 8
Dependent Claim
14 words
The peptide of any of claims 1, 2 or 3 wherein Y is Ile--Ala--Ile--Gly.
Claim 9
Dependent Claim
95 words
The peptide of claim 1 wherein the C--terminus thereof has the formula Y--CO--R.sup.1 wherein Y is as indicated; R 1 is OM or NR 2 R 3 ; where M is hydrogen, a pharmaceutically acceptable salt, or a C 1 -C 6 branched or unbranched alkyl group; and R 2 and R 3 are the same or different and selected from the group consisting of hydrogen, C 1 -C 6 branched or unbranched alkyl, or both R 2 and R 3 taken together with the nitrogen atom form a five or six membered heterocyclic ring.
Claim 10
Dependent Claim
10 words
The peptide of claim 8 wherein R 1 is OM.
Claim 11
Dependent Claim
14 words
The peptide of claim 9 wherein M is H or a pharmaceutically acceptable salt.
Claim 12
Dependent Claim
15 words
A compound of the formula ##STR6## where M is hydrogen or a pharmaceutically acceptable salt.
Claim 13
Dependent Claim
15 words
A compound of the formula ##STR6## where M is hydrogen or a pharmaceutically acceptable salt.
Claim 14
Dependent Claim
15 words
A compound of the formula ##STR7## where M is hydrogen or a phramceutically acceptable salt.
Claim 15
Dependent Claim
15 words
A compound of the formula ##STR7## where M is hydrogen or a phramceutically acceptable salt.
Claim 16
Dependent Claim
23 words
A composition useful for antiviral treatment comprising an effective amount of a peptide according to claim 1 together with a phramacologically inert carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-12-01 | 1990-06-02 | 1990-12-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-12-01 | 1994-06-02 | 1994-12-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-12-01 | 1998-06-02 | 1998-12-02 | $7700.00 | Window Closed / Lapsed |